Zacks Research Has Bearish Estimate for PAHC Q3 Earnings

Phibro Animal Health Co. (NASDAQ:PAHC) – Equities research analysts at Zacks Research cut their Q3 2025 earnings estimates for shares of Phibro Animal Health in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.35 for the quarter, down from their prior forecast of $0.37. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.61 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q1 2026 earnings at $0.32 EPS, Q3 2026 earnings at $0.33 EPS and Q1 2027 earnings at $0.48 EPS.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.07. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%. The firm had revenue of $273.16 million for the quarter, compared to analysts’ expectations of $262.44 million.

PAHC has been the topic of several other reports. StockNews.com cut shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Bank of America upped their price objective on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research report on Friday, August 30th. Barclays lifted their target price on Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. assumed coverage on Phibro Animal Health in a report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $16.50.

Phibro Animal Health Price Performance

Phibro Animal Health stock opened at $24.14 on Monday. Phibro Animal Health has a 52-week low of $9.49 and a 52-week high of $25.98. The company has a market cap of $977.67 million, a price-to-earnings ratio of 55.21, a PEG ratio of 0.61 and a beta of 0.51. The firm’s fifty day moving average is $23.16 and its 200 day moving average is $20.03. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PAHC. Jacobs Levy Equity Management Inc. increased its position in shares of Phibro Animal Health by 56.0% during the first quarter. Jacobs Levy Equity Management Inc. now owns 79,667 shares of the company’s stock worth $1,030,000 after acquiring an additional 28,584 shares during the period. Sofinnova Investments Inc. purchased a new position in Phibro Animal Health during the 2nd quarter worth $3,975,000. Acadian Asset Management LLC raised its position in Phibro Animal Health by 6.3% during the 2nd quarter. Acadian Asset Management LLC now owns 717,506 shares of the company’s stock valued at $12,027,000 after purchasing an additional 42,299 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Phibro Animal Health in the 3rd quarter worth $70,000. Finally, Dana Investment Advisors Inc. grew its position in shares of Phibro Animal Health by 17.2% during the 2nd quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock worth $8,619,000 after buying an additional 75,546 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

Insiders Place Their Bets

In related news, Director E Thomas Corcoran purchased 5,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were purchased at an average cost of $20.02 per share, for a total transaction of $100,100.00. Following the completion of the acquisition, the director now owns 25,000 shares in the company, valued at approximately $500,500. This trade represents a 25.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 50.07% of the company’s stock.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Wednesday, November 27th will be given a $0.12 dividend. This represents a $0.48 annualized dividend and a yield of 1.99%. The ex-dividend date is Wednesday, November 27th. Phibro Animal Health’s dividend payout ratio (DPR) is presently 111.63%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.